

# Leptin Receptor Gene Polymorphisms and the Risk of Non-Alcoholic Fatty Liver Disease and Coronary Atherosclerosis in the Chinese Han Population

Bai-Quan An,<sup>1</sup> Lin-Lin Lu,<sup>2,3</sup> Chen Yuan,<sup>1</sup> Yong-Ning Xin,<sup>1,2,4,\*</sup> and Shi-Ying Xuan<sup>1,2,4,\*</sup>

<sup>1</sup>Department of Gastroenterology, Qingdao Municipal College, Nanjing Medical University, Qingdao, Shandong Province, China

<sup>2</sup>Digestive Disease Key Laboratory of Qingdao, Qingdao, China

<sup>3</sup>Central Laboratories, Qingdao Municipal Hospital, Qingdao, China

<sup>4</sup>Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, China

\*Corresponding authors: Yong-Ning Xin, Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, China. Tel: +86-53288905289, Fax: +86-53288905293, E-mail: xinyongning@163.com; Shi-Ying Xuan, Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao, China. Tel: +86-53288905289, Fax: +86-53288905293, E-mail: xuansydx@163.com

Received 2015 November 27; Revised 2016 January 26; Accepted 2016 February 05.

## Abstract

**Background:** Leptin receptor (*LEPR*) polymorphisms have been reported to be associated with lipid metabolism and insulin resistance in various populations. However, whether *LEPR* polymorphisms are associated with the risks of non-alcoholic fatty liver disease (NAFLD) and coronary atherosclerosis in the Chinese Han population remains unknown.

**Objectives:** To investigate the association of *LEPR* polymorphisms at Q223R and K109R with the risks of NAFLD and coronary atherosclerosis in the Chinese Han population.

**Patients and Methods:** Genotypes of *LEPR*Q223R and *K109R* were determined by polymerase chain reaction followed by sequencing in patients with NAFLD (n = 554), coronary atherosclerosis (n = 421), and healthy controls (n = 550). Serum lipid profiles were determined using biochemical methods. Pearson's  $\chi^2$  test was used to check for Hardy-Weinberg equilibrium and to analyze the distributions of genotypes' alleles between groups. Baseline characteristics were analyzed using student's t-test, paired-samples t-test, or the  $\chi^2$  test where appropriate.

**Results:** The *LEPR*Q223R A allele significantly reduced the risks of both NAFLD and coronary atherosclerosis (OR = 0.683, 95% CI: 0.527 - 0.884, P = 0.004 and OR = 0.724, 95% CI: 0.548 - 0.955, P = 0.022, respectively). Compared to controls, no significant differences in the genotype and allele frequencies of *K109R* were found in the NAFLD and coronary atherosclerosis populations, respectively. However, there was a significantly increased risk of coronary atherosclerosis in NAFLD patients who carried the *K109R* A allele (OR = 2.283, 95% CI: 1.556 - 3.348, P < 0.001).

**Conclusions:** *LEPR* Q223R polymorphisms may confer a significant risk of NAFLD and coronary atherosclerosis. The A allele in the *K109R* polymorphism might be considered an independent risk factor for coronary atherosclerosis in NAFLD patients.

**Keywords:** Non-Alcoholic Fatty Liver Disease, Coronary Atherosclerosis, Single Nucleotide Polymorphism, *LEPR*

## 1. Background

Both non-alcoholic fatty liver disease (NAFLD) and coronary atherosclerosis belong to the category of metabolic syndrome (MS). NAFLD increases the risk of coronary atherosclerosis, which is one of the leading causes of death resulting from NAFLD (1). The risk factors for NAFLD, such as metabolic disorders of lipids and insulin resistance, are frequently accompanied by coronary atherosclerosis. Both NAFLD and coronary atherosclerosis have a strong genetic component, and their inheritance is polygenic (2). In general, NAFLD and coronary atherosclerosis share a common genetic background, i.e., the risk alleles for NAFLD may also be involved in the increased risk of coronary atherosclerosis (2, 3).

The leptin receptor gene (*LEPR*), responsible for encoding the leptin receptor that binds to leptin in target tissues, is believed to be a candidate gene for NAFLD as well as coronary atherosclerosis because of its role in regulation of lipid metabolism and insulin resistance (4). However, few studies have examined the association of the *LEPR* K109R and Q223R polymorphisms with the risks of coronary atherosclerosis and NAFLD in the Chinese Han population. In addition, the potential link between *LEPR* polymorphisms and the risk of developing coronary atherosclerosis in NAFLD is largely unknown.

## 2. Objectives

The purpose of the present study was to investigate the association between *LEPR* K109R and Q223R polymorphisms and the susceptibility to NAFLD and coronary atherosclerosis, respectively, in the Chinese Han population. Our findings may ultimately provide novel means to combat the development of coronary atherosclerosis and NAFLD.

## 3. Patients and Methods

### 3.1. Study Design

A total of 554 NAFLD patients (269 males, 285 females) and 421 coronary atherosclerosis patients (214 males, 207 females) were selected from the Qingdao area of China. The study design was described in detail previously (2, 5). Based on previous studies, we enlarged the sample size to ensure that the statistical power was greater than 80 percent. NAFLD was diagnosed under standard clinical evaluation according to the Chinese association of medicine in 2010 (6). Coronary atherosclerosis was diagnosed using a percutaneous coronary angiogram and defined by the presence of at least 50% stenosis in at least one of the coronary arteries. We also recruited 550 healthy control volunteers (276 males, 274 females) from the medical center of Qingdao Municipal hospital. The healthy participants were carefully chosen according to their medical history, general examinations, and laboratory examinations. All subjects were screened for fatty liver by abdominal ultrasound examinations and excluded, as previously described (2). All patients and controls enrolled in this study were recruited from the same population and signed a written consent form. The study was conducted according to the principles of the declaration of Helsinki. Body height and weight were measured to calculate the body mass index (BMI, weight/height<sup>2</sup>). Blood samples were obtained from each subject using anticoagulative tubes after a 12-hour fasting in the morning. The levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were also measured, as previously described (7).

### 3.2. Genotyping

Genomic DNA was extracted from peripheral blood leucocytes using the genomic DNA extraction kit (Beijing Bioteke biotechnology, Beijing, China). The primers for PCR amplification of the fragments containing K109R and Q223R were synthesized by Shanghai Sangon Biotech company: K109R, 5'-TCCACTGTTGCTTCGGAGTGA-3' (forward),

5'-TTCAAAGCAAATTTAGAAGACTACAAGGAATG-3' (reverse); Q223R, 5'-ACCTTTAAGCTGGGTGTCCCAATAG-3' (forward), 5'-AGCTAGCAAATATTTTGTGAAGCAATT-3' (reverse). Each 10  $\mu$ L reaction contained 1x GC-I buffer, 3.0 mM of Mg<sup>2+</sup>, 0.3 mM of dNTP, 1 U of HotStarTaq polymerase, 1  $\mu$ L of DNA samples, and 1  $\mu$ L of multiple PCR primers. The PCR amplification profile was shown below 35 cycles of 95°C for 2 minutes, 94°C for 20 seconds, 65°C for 40 seconds, 72°C for 90 seconds, and 72°C for 2 minutes. After purification, multiple PCR products were used to perform the coupled reaction. The PCR amplification conditions were 38 cycles of 94°C for 1 minute and 56°C for 4 minutes. The *LEPR* gene was sequenced using the ABI3730XL sequencer (Foster city, CA, USA).

### 3.3. Statistical Analysis

Genotypes and alleles were estimated by counting and Hardy-Weinberg equilibrium was determined using Pearson's  $\chi^2$  test. Baseline characteristics were shown as mean  $\pm$  SD and analyzed using Student's t-test, paired-samples t-test, or the  $\chi^2$  test where appropriate. In addition, the chi-squared test was used to compare the distribution of genotypes and alleles in different groups. The risks of NAFLD and coronary atherosclerosis were estimated using the odds ratio (OR) with a 95% confidence interval (CI). The significance level was defined as  $P < 0.05$ .

## 4. Results

### 4.1. Characteristics of the Study Population

From these subjects, healthy controls were matched for sex and age with NAFLD or coronary atherosclerosis patients (all  $P > 0.05$ ). The characteristics of the study population are shown in the Table 1.

### 4.2. Genotype and Allele Distributions of *LEPR* Polymorphisms

Distributions of the genotypes of *LEPR* polymorphisms were in accordance with the Hardy-Weinberg equilibrium in study groups ( $P > 0.05$ ). As shown in Table 2, the Q223R polymorphism was significantly associated with NAFLD and coronary atherosclerosis. Carriers of the A allele had a reduced risk of NAFLD (OR = 0.683, 95% CI: 0.527 - 0.884,  $P = 0.004$ ) and coronary atherosclerosis (OR = 0.724, 95%CI: 0.548 - 0.955,  $P = 0.022$ ) compared with non-carriers. In contrast, no significant differences were found for the K109R polymorphism in NAFLD and coronary atherosclerosis patients compared to the controls (Table 2). However, a significant association was observed between NAFLD subjects with and without coronary atherosclerosis in the K109R polymorphism. NAFLD patients with the K109R A allele were likely to develop coronary atherosclerosis (OR = 2.283, 95% CI: 1.556 - 3.348,  $P < 0.001$ , Table 3).

**Table 1.** Comparison of Demographic and Basal Characteristics Among Study Groups<sup>a</sup>

Characteristics	NAFLD, (n = 554)	Coronary Atherosclerosis, (n = 421)	Control, (n = 550)	P1	P2	P3
<b>Gender</b>				0.589	0.841	0.482
M	269	214	276			
F	285	207	274			
<b>Age, y</b>	46.44 ± 16.77	46.57 ± 11.73	46.45 ± 12.01	0.982	0.887	0.869
<b>BMI, kg/m<sup>2</sup></b>	24.23 ± 1.66	24.07 ± 1.63	23.48 ± 1.70	< 0.001	< 0.001	0.138
<b>ALT, U/L</b>	23.52 ± 10.40	21.57 ± 12.82	20.13 ± 9.94	< 0.001	0.122	0.001
<b>AST, U/L</b>	21.45 ± 6.47	19.93 ± 9.32	19.44 ± 5.17	< 0.001	0.327	0.004
<b>FPG, mmol/L</b>	5.18 ± 0.76	5.33 ± 3.04	4.94 ± 0.58	< 0.001	0.008	0.298
<b>TG, mmol/L</b>	1.80 ± 1.58	1.58 ± 1.40	1.39 ± 1.52	< 0.001	0.053	0.025
<b>TC, mmol/L</b>	4.79 ± 0.99	4.48 ± 1.03	4.46 ± 0.96	< 0.001	0.710	< 0.001
<b>HDL, mmol/L</b>	1.35 ± 0.59	1.41 ± 0.47	1.47 ± 0.32	< 0.001	0.033	0.091
<b>LDL, mmol/L</b>	3.43 ± 0.96	3.00 ± 1.05	2.86 ± 0.72	< 0.001	0.012	< 0.001

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; FPG, fasting blood glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease patients; P1, NAFLD group vs. control group; P2, coronary atherosclerosis group vs. control group; P3, NAFLD group vs. coronary atherosclerosis group; TG, triglyceride; TC, total cholesterol.

<sup>a</sup>Values are expressed as mean ± SD.

**Table 2.** Distribution of *LEPR* K109R and Q223R Polymorphisms in Study Groups<sup>a</sup>

Genotype	NAFLD, (n = 554)	Coronary Atherosclerosis, (n = 421)	Control, (n = 550)	P1	OR (95% CI)	P2	OR (95% CI)
<b>K109R</b>							
GG	356 (64.3)	295 (70.1)	371 (67.5)				
GA	178 (32.1)	110 (26.1)	157 (28.5)				
AA	20 (3.6)	16 (3.8)	22 (4.0)				
AA+GA/GG	198/356	126/295	179/371	0.263	1.153 (0.899 - 1.479)	0.384	0.885 (0.673 - 1.165)
GG+GA/AA	534/20	405/16	528/22	0.735	1.113 (0.600 - 2.063)	0.874	1.055 (0.547 - 2.034)
A/G	218/890	142/700	201/899	0.401	1.096 (0.885 - 1.355)	0.42	0.907 (0.716 - 1.149)
<b>Q223R</b>							
GG	409 (73.8)	306 (72.7)	362 (65.8)				
GA	129 (23.3)	103 (24.5)	162 (29.5)				
AA	16 (2.9)	12 (2.8)	26 (4.7)				
AA+GA/GG	145/409	115/306	188/362	0.004	0.683 (0.527 - 0.884)	0.022	0.724 (0.548 - 0.955)
GG+GA/AA	538/16	409/12	524/26	0.110	1.668 (0.885 - 3.146)	0.135	1.691 (0.843 - 3.392)
A/G	161/947	127/715	214/886	0.002	0.704 (0.563 - 0.881)	0.012	0.735 (0.578 - 0.935)

Abbreviations: NAFLD, non-alcoholic fatty liver disease patients; OR, odds ratio; P1, NAFLD group vs. control group; P2, coronary atherosclerosis group vs. control group.

<sup>a</sup>Values are expressed as No. (%).

#### 4.3. Association Between *LEPR* Genotypes and the Clinical Characteristics

We compared the *LEPR* genotypes with the clinical characteristics among different study groups to investigate whether *LEPR* polymorphisms affected the clinical manifestations of NAFLD and coronary atherosclerosis (Ta-

bles 4 and 5). Compared with the non-carriers, higher levels of the lipid variables (BMI, FPG, TG, and TC) were observed in K109R A allele carriers who were NAFLD patients with coronary atherosclerosis. Furthermore, the serum AST level was significantly higher in K109R A allele carriers who were NAFLD patients with coronary atherosclerosis.

**Table 3.** Distribution of *LEPR* K109R Genotypes in NAFLD Patients With and Without Coronary Atherosclerosis<sup>a</sup>

Genotype, (K109R)	NAFLD <sup>+</sup> , Coronary Atherosclerosis <sup>+</sup> , (n = 349)	NAFLD <sup>+</sup> , Coronary Atherosclerosis <sup>-</sup> , (n = 205)	P Value	OR (95% CI)
GG	201(57.6)	155 (75.6)		
GA	133(38.1)	45 (22.0)		
AA	15(4.3)	5 (2.4)		
AA+GA/GG	148/201	50/155	< 0.001	2.283 (1.556 - 3.348)
GG+GA/AA	334/15	200/5	0.257	0.557 (0.199 - 1.555)
A/G	169/529	55/355	< 0.001	2.062 (1.479 - 2.876)

Abbreviations: NAFLD+ coronary atherosclerosis+, non-alcoholic fatty liver disease patients with coronary atherosclerosis group; NAFLD+ coronary atherosclerosis- , NAFLD patients without coronary atherosclerosis group; OR, odds ratio.

<sup>a</sup>Values are expressed as No. (%).

sis than in NAFLD patients without coronary atherosclerosis (Table 4). Thus, we conclude that the K109R A allele promotes the clinical manifestations of an altered lipid profile in NAFLD patients. NAFLD and coronary atherosclerosis are two main diseases in the category of metabolic syndrome (MS), so we merged NAFLD and coronary atherosclerosis groups to explore the association between the clinical parameters and *LEPR* genotypes. Compared with controls, the K109R A allele carriers who were NAFLD and coronary atherosclerosis patients showed higher levels of BMI, ALT, AST, TG, TC, and LDL and lower levels of HDL (All  $P < 0.05$ ), and Q223R A carriers had lower level of ALT ( $P = 0.004$ ) and higher level of HDL ( $P = 0.002$ ), although there were no significant differences in the levels of BMI, ALT, TG, TC, and LDL between Q223R A allele carriers and controls (Table 5).

## 5. Discussion

The present study evaluated the association of the *LEPR* gene polymorphisms (K109R and Q223R) with the risks of both NAFLD and coronary atherosclerosis in the Chinese Han population. We summarized the key findings as follows: First, carriers of the Q223R A allele had lower susceptibilities to NAFLD and coronary atherosclerosis, respectively, in the Chinese Han population. Second, the K109R A allele was associated with a high risk of coronary atherosclerosis in NAFLD patients.

The *LEPR* gene, a member of cytokine-receptor family, is located on chromosome 1p31 and plays an important role in regulating body weight and energy expenditure (8, 9). Previous studies have shown that *LEPR*-K109R and -Q223R polymorphisms were risk factors of metabolic syndrome, including obesity (10-12), increased body weight and BMI (13), and an altered serum lipid profile (14), while the association between these two polymorphisms and NAFLD or coronary atherosclerosis were not clear.

In 2013, Zain et al. first reported that both K109R and Q223R SNPs were associated with an increased risk of NAFLD in the Malaysian population (15). In the Chinese population, the Q223R GG, but not the K109R polymorphism significantly increased the risk of NAFLD (16, 17). In accordance with previous observations, we found that the Q223R, but not the K109R polymorphism was associated with an increased incidence of NAFLD. We also found that subjects carrying the Q223R A allele (AA+GA) had a lower risk of NAFLD than those carrying the GG homozygote ( $P = 0.004$ ), which was different from previous reports (15-17). This discrepancy may be attributed to the regional and/or ethnic differences in these studies.

Coronary atherosclerosis usually shares a common genetic background with NAFLD. In 2009, a Czech study suggested that *LEPR* Q223R was a susceptibility modulating factor of ischemic heart disease or dilated cardiomyopathy patients (18). In 2010, Saukko et al. suggested that both Q223R and K109R polymorphisms were associated with early atherosclerosis independently in Finland (19). However, another study in 2013 found that the K109R GG homozygote reduced the incidence of coronary heart disease (CHD) and mortality (20). In the Chinese population, Gu et al. first reported that Q223R (AA+AG) increased the risk of essential hypertension (EH) compared with the GG polymorphism (21). In apparent disagreement with these results, Liu et al. reported that Q223R G allele carriers more likely suffered from EH (22), while no association was found between the K109R polymorphism and EH. In the present study, we found that Q223R A carriers had a reduced risk of coronary atherosclerosis in the Chinese Han population. Although the K109R polymorphism was not associated with either NAFLD or coronary atherosclerosis, the frequency of K109R A alleles in NAFLD patients with CAD was substantially higher than those without coronary atherosclerosis, suggesting that the K109R polymorphism potentially contributes to the pathogenesis of coronary

**Table 4.** Association of *LEPR* K109R Genotypes With Clinical Pathological Parameters in NAFLD Patients With and Without Coronary Atherosclerosis<sup>a</sup>

Clinical Characteristics	NAFLD <sup>+</sup> Coronary Atherosclerosis <sup>+</sup>			NAFLD <sup>+</sup> Coronary Atherosclerosis <sup>-</sup>		
	AA+GA, (n = 148)	GG, (n = 201)	P Value	AA+GA, (n = 50)	GG, (n = 155)	P Value
<b>Gender</b>			0.650			0.962
Male	70	100		24	75	
Female	78	101		26	80	
<b>Age, y</b>	45.28 ± 11.59	47.00 ± 12.28	0.184	48.88 ± 10.32	46.04 ± 11.65	0.105
<b>BMI, kg/m<sup>2</sup></b>	24.67 ± 1.59	24.07 ± 1.69	0.001	24.34 ± 1.62	23.98 ± 1.65	0.176
<b>ALT, U/L</b>	24.72 ± 11.73	22.80 ± 9.98	0.096	25.94 ± 13.30	22.52 ± 8.47	0.092
<b>AST, U/L</b>	22.22 ± 6.93	20.79 ± 5.50	0.039	23.60 ± 9.01	20.86 ± 6.03	0.049
<b>FPG, mmol/L</b>	5.31 ± 0.84	5.02 ± 0.67	0.001	5.39 ± 0.92	5.18 ± 0.71	0.094
<b>TG, mmol/L</b>	2.06 ± 2.12	1.69 ± 1.18	0.039	2.00 ± 2.13	1.61 ± 1.13	0.101
<b>TC, mmol/L</b>	4.96 ± 1.02	4.75 ± 0.96	0.051	4.92 ± 0.87	4.64 ± 1.01	0.084
<b>HDL, mmol/L</b>	1.34 ± 0.71	1.40 ± 0.63	0.416	1.22 ± 0.31	1.35 ± 0.49	0.068
<b>LDL, mmol/L</b>	3.55 ± 0.95	3.47 ± 0.98	0.456	3.32 ± 1.08	3.30 ± 0.88	0.873

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; FPG, fasting blood glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease patients; P1, NAFLD group vs. control group; P2, coronary atherosclerosis group vs. control group; P3, NAFLD group vs. coronary atherosclerosis group; TG, triglyceride; TC, total cholesterol.

<sup>a</sup>Values are expressed as mean ± SD.

**Table 5.** Determination of *LEPR* K109R and Q223R Polymorphisms as Risk Factors for Both NAFLD and Coronary Atherosclerosis at Baseline<sup>a</sup>

Clinical Characteristics	K109R			Q223R		
	AA+GA, (n = 324)	GG, (n = 651)	P Value	AA+GA, (n = 260)	GG, (n = 715)	P Value
<b>Gender</b>			0.540			0.401
M	156	327		123	360	
F	168	324		137	355	
<b>Age, y</b>	46.81 ± 11.24	46.34 ± 12.00	0.546	46.50 ± 11.76	45.92 ± 11.15	0.864
<b>BMI, kg/m<sup>2</sup></b>	24.37 ± 1.62	24.05 ± 1.66	0.004	24.09 ± 1.76	24.16 ± 1.65	0.881
<b>ALT, U/L</b>	23.60 ± 10.68	21.96 ± 10.80	0.025	17.75 ± 4.58	22.56 ± 10.82	0.004
<b>AST, U/L</b>	21.75 ± 6.82	20.32 ± 8.29	0.007	19.25 ± 4.31	20.81 ± 7.89	0.494
<b>FPG, mmol/L</b>	5.27 ± 0.89	5.23 ± 2.46	0.734	4.83 ± 0.39	5.25 ± 2.09	0.486
<b>TG, mmol/L</b>	1.92 ± 1.82	1.59 ± 1.31	0.004	1.30 ± 0.71	1.71 ± 1.51	0.354
<b>TC, mmol/L</b>	4.82 ± 0.99	4.57 ± 1.02	0.001	4.51 ± 0.87	4.65 ± 1.02	0.600
<b>HDL, mmol/L</b>	1.33 ± 0.64	1.41 ± 0.49	0.031	1.86 ± 1.27	1.37 ± 0.53	0.002
<b>LDL, mmol/L</b>	3.48 ± 0.95	3.13 ± 1.04	< 0.001	3.23 ± 1.01	3.25 ± 1.02	0.951

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; FPG, fasting blood glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease patients; P1, NAFLD group vs. control group; P2, coronary atherosclerosis group vs. control group; P3, NAFLD group vs. coronary atherosclerosis group; TG, triglyceride; TC, total cholesterol.

<sup>a</sup>Values are expressed as mean ± SD.

atherosclerosis in NAFLD patients.

In the present study, compared with the non-carriers, the K109R A allele carriers who were NAFLD or coronary atherosclerosis patients showed higher levels of BMI, ALT,

AST, TG, TC, and LDL and lower levels of HDL. In addition, Q223R A carriers had significantly lower level of ALT and higher level of HDL than controls. The mechanisms associated with the disturbance of lipid metabolism are not



fully understood. However, it is possible that the polymorphism affects the activity of LEPR in modifying leptin-mediated signaling that induces feeding behavior and energy metabolism changes. Insulin resistance is recognized as an essential pathophysiological factor in the development of both NAFLD and coronary atherosclerosis. In this study, detrimental effects of the K109R A allele on the FPG levels of NAFLD patients with coronary atherosclerosis were observed, suggesting that the K109R A allele may potentially contribute to insulin resistance in coronary atherosclerosis patients, which in turn, may promote the risk of cardiovascular complications.

The major limitation of this study is the lack of a liver biopsy to diagnose NAFLD, although NAFLD was diagnosed by ultrasonography and analyzed by two experienced doctors. In addition, the size of samples in our study was not sufficiently large to comprehensively analyze the associations.

In summary, the present study provided preliminary evidence revealing the association between *LEPR* Q223R polymorphisms and the lower risks of both NAFLD and coronary atherosclerosis in the Chinese population. Moreover, the *LEPR* K109R A allele increases the risk of coronary atherosclerosis in NAFLD patients, which may provide a useful genetic marker locus to identify patients at higher risk of coronary atherosclerosis. However, further investigations are needed to determine the underlying mechanisms.

## Footnotes

**Authors' Contribution:** Study concept and design, Bai-Quan An and Yong-Ning Xin; acquisition of the data, Bai-Quan An, Chen Yuan, and Lin-Lin Lu; analysis and interpretation of the data; Bai-Quan An and Lin-Lin Lu; drafting of the manuscript; Bai-Quan An and Lin-Lin Lu; critical revision of the manuscript for important intellectual content: Shi-Ying Xuan; statistical analysis, Bai-Quan An and Chen Yuan; administrative, technical, and material support, Yong-Ning Xin; study supervision: Shi-Ying Xuan.

**Funding/Support:** This study was supported by the Qingdao Livelihood, science, and technology project, China (Grant No. 14-2-3-17-nsh) and the Qingdao key health discipline development fund.

## References

1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med*. 2010;**363**(14):1341-50. doi: [10.1056/NEJMra0912063](#). [PubMed: [20879883](#)].
2. Cheng Y, An B, Jiang M, Xin Y, Xuan S. Association of Tumor Necrosis Factor- $\alpha$  Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease. *Hepat Mon*. 2015;**15**(3):e26818. doi: [10.5812/hepatmon.26818](#). [PubMed: [25825591](#)].
3. Petta S, Valenti L, Marchesini G, Di Marco V, Licata A, Camma C, et al. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. *PLoS One*. 2013;**8**(9):e74089. doi: [10.1371/journal.pone.0074089](#). [PubMed: [24069270](#)].
4. Aller R, De Luis DA, Izaola O, Gonzalez Sagrado M, Conde R, Pacheco D, et al. Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease. *Eur Rev Med Pharmacol Sci*. 2012;**16**(3):335-41. [PubMed: [22530350](#)].
5. Niu TH, Jiang M, Xin YN, Jiang XJ, Lin ZH, Xuan SY. Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. *World J Gastroenterol*. 2014;**20**(13):3655-62. doi: [10.3748/wjg.v20.i13.3655](#). [PubMed: [24707151](#)].
6. Jian-gao F, Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. *Zhonghua Gan Zang Bing Za Zhi*. 2010;**18**(3):163-6. [PubMed: [20698076](#)].
7. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. *J Clin Endocrinol Metab*. 2007;**92**(9):3490-7. doi: [10.1210/jc.2007-0482](#). [PubMed: [17595248](#)].
8. Dias NF, Fernandes AE, Melo ME, Reinhardt HL, Cercato C, Villares SM, et al. Lack of mutations in the leptin receptor gene in severely obese children. *Arq Bras Endocrinol Metabol*. 2012;**56**(3):178-83. [PubMed: [22666733](#)].
9. Salopuro T, Pulkkinen L, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, et al. Genetic variation in leptin receptor gene is associated with type 2 diabetes and body weight: The Finnish Diabetes Prevention Study. *Int J Obes (Lond)*. 2005;**29**(10):1245-51. doi: [10.1038/sj.ijo.0803024](#). [PubMed: [15997246](#)].
10. Mizuta E, Kokubo Y, Yamanaka I, Miyamoto Y, Okayama A, Yoshimasa Y, et al. Leptin gene and leptin receptor gene polymorphisms are associated with sweet preference and obesity. *Hypertens Res*. 2008;**31**(6):1069-77. doi: [10.1291/hyres.31.1069](#). [PubMed: [18716353](#)].
11. Ukkola O, Bouchard C. Role of candidate genes in the responses to long-term overfeeding: review of findings. *Obes Rev*. 2004;**5**(1):3-12. [PubMed: [14969502](#)].
12. Tabassum R, Mahendran Y, Dwivedi OP, Chauhan G, Ghosh S, Marwaha RK, et al. Common variants of IL6, LEPR, and PBEF1 are associated with obesity in Indian children. *Diabetes*. 2012;**61**(3):626-31. doi: [10.2337/db11-1501](#). [PubMed: [22228719](#)].
13. Furusawa T, Naka I, Yamauchi T, Natsuhara K, Kimura R, Nakazawa M, et al. The Q223R polymorphism in LEPR is associated with obesity in Pacific Islanders. *Hum Genet*. 2010;**127**(3):287-94. doi: [10.1007/s00439-009-0768-9](#). [PubMed: [20183928](#)].
14. Okada T, Ohzeki T, Nakagawa Y, Sugihara S, Arisaka O, Study Group of Pediatric O, et al. Impact of leptin and leptin-receptor gene polymorphisms on serum lipids in Japanese obese children. *Acta Paediatr*. 2010;**99**(8):1213-7. doi: [10.1111/j.1651-2227.2010.01778.x](#). [PubMed: [20222875](#)].
15. Zain SM, Mohamed Z, Mahadeva S, Cheah PL, Rampal S, Chin KF, et al. Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with adiponutrin gene. *J Gastroenterol Hepatol*. 2013;**28**(5):873-9. doi: [10.1111/jgh.12104](#). [PubMed: [23278404](#)].
16. Zhang C, Guo L, Guo X. [Interaction of polymorphisms of Leptin receptor gene Gln223Arg, MnSOD9Ala/Val genes and smoking in nonalcoholic fatty liver disease]. *Wei Sheng Yan Jiu*. 2014;**43**(5):724-31. [PubMed: [25508055](#)].
17. Chen SH, Li YM, Jiang LL, Yu CH. [Evaluation of leptin receptor Lys109Arg polymorphism in patients with non-alcoholic fatty liver disease]. *Zhonghua Gan Zang Bing Za Zhi*. 2006;**14**(6):453-5. [PubMed: [16792872](#)].
18. Bienertova-Vasku JA, Spinarova L, Bienert P, Vasku A. Association between variants in the genes for leptin, leptin receptor, and proopiomelanocortin with chronic heart failure in the Czech population. *Heart Vessels*. 2009;**24**(2):131-7. doi: [10.1007/s00380-008-1090-5](#). [PubMed: [19337797](#)].

19. Saukko M, Kesaniemi YA, Ukkola O. Leptin receptor Lys109Arg and Gln223Arg polymorphisms are associated with early atherosclerosis. *Metab Syndr Relat Disord*. 2010;**8**(5):425-30. doi: [10.1089/met.2010.0004](https://doi.org/10.1089/met.2010.0004). [PubMed: [20874424](https://pubmed.ncbi.nlm.nih.gov/20874424/)].
20. Aijala M, Santaniemi M, Bloigu R, Kesaniemi YA, Ukkola O. Leptin receptor Arg109 homozygotes display decreased total mortality as well as lower incidence of cardiovascular disease and related death. *Gene*. 2014;**534**(1):88-92. doi: [10.1016/j.gene.2013.10.003](https://doi.org/10.1016/j.gene.2013.10.003). [PubMed: [24140454](https://pubmed.ncbi.nlm.nih.gov/24140454/)].
21. Gu P, Jiang W, Chen M, Lu B, Shao J, Du H, et al. Association of leptin receptor gene polymorphisms and essential hypertension in a Chinese population. *J Endocrinol Invest*. 2012;**35**(9):859-65. doi: [10.3275/8238](https://doi.org/10.3275/8238). [PubMed: [22293279](https://pubmed.ncbi.nlm.nih.gov/22293279/)].
22. Liu Y, Lou YQ, Liu K, Liu JL, Wang ZG, Wen J, et al. Role of leptin receptor gene polymorphisms in susceptibility to the development of essential hypertension: a case-control association study in a Northern Han Chinese population. *J Hum Hypertens*. 2014;**28**(9):551-6. doi: [10.1038/jhh.2013.149](https://doi.org/10.1038/jhh.2013.149). [PubMed: [24522342](https://pubmed.ncbi.nlm.nih.gov/24522342/)].

Archive of SID